The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology, Inflammation and Beyond...

Uniting leading experts from pharma, biotech, and academia, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T cells, this forum dives into myeloid reprogramming, cell state heterogeneity, and translational challenges to unlock next-generation immune modulation.

With breakthrough insights from Eli Lilly, AbbVie, Pfizer, AstraZeneca, and Faron, and cutting-edge academic labs, this is your opportunity to explore clinical case studies, dissect failed monotherapy lessons, and gain clarity on patient stratification, trial design, and combination strategies.

So, why now?

From solid tumor immunotherapy to fibrotic disease, myeloid biology is proving pivotal. Yet many programs stall due to poor translation, limited biomarkers, and inadequate models. This Summit brings the community together to tackle these hurdles head-on, and propel the next wave of successful myeloid therapeutics forward.